Author:
Blake Catherine,Kehm Rebecca
Funder
National Science Foundation
Subject
Health Informatics,Computer Science Applications
Reference35 articles.
1. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, F. a. D. A. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2007.
2. Review of survival analyses published in cancer journals;Altman;Br. J. Cancer,1995
3. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration;Altman;PLoS Med.,2012
4. Effective Mapping of Biomedical Text to the UMLS Metathesaurus: The MetaMap Program;Aronson,2001
5. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials;Bellera;Eur. J. Cancer,2013